重组人血管内皮抑制素联合TC方案治疗晚期非小细胞肺癌的临床观察

Observation of rh-endostatin combined with TC regimen for non-small cell lung cancer

目的:观察重组人血管内皮抑制素(恩度)联合TC方案(紫杉醇+卡铂)治疗晚期非小细胞肺癌(NSCLC)的近期疗效及安全性。方法:采用TC+恩度(试验组)和TC(对照组)治疗晚期NSCLC共53例,治疗2～6疗程。按照RECIST标准和NCI-CTC标准分别评价疗效和毒性。结果:试验组有效率为59.3%,疾病控制率为81.5%,对照组的有效率为30.8%,疾病控制率为53.8%。毒副反应主要有白细胞减少、血小板减少、恶心呕吐、肌肉关节酸痛和心血管毒性等。结论:恩度与TC方案联合治疗晚期NSCLC的近期客观疗效较高,且安全性较好。

Objective：To observe the short-term efficacy and safety of rh-endostain（endostar） combined with TC regimen in patients with advanced non-small cell lung cancer（NSCLC）.Methods：Fifty-three patients with stage ⅢB-Ⅳ NSCLC were divided into TC＋endostar group（trial group） and TC group（control group）,the efficacy and toxicity were evaluated after 2-4 cycles according to RECIST criteria.Results：The response rates were 59.3% in trial group and 30.8% in control group.The clinical benefit rates were 81.5% in trial group and 53.8% in control group.The major side effects were neutropenia,thrombocytopenia,nausea,vomiting,muscular soreness and cardiovascular toxicity.Conclusion：Endostar combined TC regimen were effective,and the toxicity was tolerable.